Combination therapies of DPP4 inhibitors and GLP1 analogues with insulin in type 2 diabetic patients: a systematic review. Curr Vasc Phar- macol 2013; 11: 992-1000.Rizos EC, Ntzani EE, Papanas N, et al.-- Combination therapies of DPP4 inhibitors and GLP1 analogues with insulin in...
LBIS®胰高血糖素样肽-1(GLP-1)(活性) ELISA 试剂盒 胰高血糖素样肽-1(Glucagon-like peptide-1,GLP-1)是胰高血糖素前驱体的一部分。胰高血糖素前驱体于胰脏、小肠下部以及下丘脑中表达。该前驱体的构造中含有与糖代谢有关的各种各样的生理活性物质(胰高血糖素,肠高血糖素,胃泌酸调节素,GLP-1,GLP-2...
kidney disease. As GLP-1 has been implicated as a mediator in the putative gut–renal axis (a rapid-acting feed-forward loop that regulates postprandial fluid and electrolyte homeostasis), direct actions on the kidney have been proposed. Here, we review the role of GLP-1 and the actions of...
According to their pharmacodynamics and pharmacokinetic properties, the GLP-1RAs are categorized as either short-acting or long-acting agents. Short-acting GLP-1RAs, such as exenatide and lixisenatide, have a half-life of 2–4 h, requiring daily administration once or twice a day. Long-acting ...
induced MI in wild type mice and in mice treated with the DPP-4i inhibitor sitagliptin or with genetic deletion of DPP-4 (dpp4−/−) after induction of diabetes with high-fat diet and streptozotocin. Dpp4−/− mice showed an increased survival after MI compared with dpp4+/+ mice ...
Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease. Baumeier C, Schluter L, Saussenthaler S, Laeger T, Rodiger M, Alaze SA, Fritsche L, Haring HU, Stefan N, Fritsche A, Schwenk RW, Schurmann A. Mol Metab. 2017 Oct;6(10):1254-1263. ...
DPP4 cleaves 2 N-terminal amino acids of GLP-17–37 and GLP-17–36amide to produce GLP-19–37 and GLP-19–36amide, respectively, which act as low-affinity ligands for the GLP-1 receptor (43). Additionally, both the active and degraded forms of GLP-1 are cleared from the circulation ...
2. Insulinotropic potency of GLP-1 decrease in T2DM. 3. GLP-1 receptor agonists and DPP4-inhibitor direct the T2DM therapies. 4. Increasing the endogenous production of GLP-1 through increasing the L-cells may be an effective therapeutic approach to managing T2DM.Similar...
DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat. Obesity (Silver Spring). 2014;22(10):2172–9. Article CAS Google Scholar Joo KW, Kim S, Ahn S-Y, Chin HJ, Chae D-W, Lee J, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney ...
The first DPP-IV inhibitor to become available for clinical use was Sitagliptin in 2006 which is also used in combination with Metformin and SGLT-2 inhibitors for glycaemic control. Other DPP-IV inhibitors, such as, Litagliptin, Saxagliptin are approved by U.S. FDA for glycaemic control ...